Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

NCT07223697 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07223697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Recruiting
Start date
January 8, 2026
Completion date
March 1, 2033
Enrollment
120 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis